Tyrosine Kinase 2

临床试验

计划入组 10 人 · 首次发布于 2024 年 12 月 10 日

Unknown

NCT04179656

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

计划入组 100 人 · 首次发布于 2019 年 11 月 27 日

终止

NCT06281106

TYK2 Inhibition in Paradoxical Psoriasis

计划入组 2 人 · 首次发布于 2024 年 2 月 28 日

药物

查看全部 7707 →

Biotech

Investigational

Cinrebafusp alfa

化学药品

Investigational

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

相关疾病：Acute Renal Dysfunction, Renal Failure, Chronic Renal Failure

C₉H₁₁NO₃

Biotech

Investigational

Anvatabart opadotin

机构

查看全部 1398 →

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

资讯

查看全部 14642 →

8个月前

Alumis to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

去年

Alumis' Oral TYK2 Inhibitor ESK-001 Shows Sustained Efficacy in Psoriasis Phase 2 Extension

去年

临床试验

Tyrosine Kinase 2 (TYK2) for GA and CS

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

TYK2 Inhibition in Paradoxical Psoriasis

药物

Cinrebafusp alfa

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

Anvatabart opadotin

机构

MEREO BIOPHARMA 2 LIMITED

UpJohn US 2 LLC

RIVER 2 RENAL CORP.

资讯

Alumis to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis' Oral TYK2 Inhibitor ESK-001 Shows Sustained Efficacy in Psoriasis Phase 2 Extension

Takeda's Oral TYK2 Inhibitor Zasocitinib Advances Development for Multiple Autoimmune Conditions